SBCF Glasgow Project

SBCF Glasgow Project; Project update for media, December 2020.

The University of Glasgow led team, who are working hard to develop synthetic bone for use by trauma surgeons to repair the limbs of landmine victims, have reached an exciting new milestone of the project – the contract signing of new project partners, Histocell.

Histocell´s Chief Scientific Officer, Dr. Castro (Project PI), next to the company clean room.

Histocell S.L is a cell therapy company Authorised to produce Advanced Therapy Medicinal Products under investigation by the Spanish Medicines Agency (AEMPS). The company has been working more than 10 years on bone regeneration and has developed an innovative autologous cell therapy product based on a combination of adipose tissue derived mesenchymal styem cells and a novel patented bone substitute with optimal bone remodelling properties.

In the framework of SBCF Glasgow Project, and taking advantage of its expertise, Histocell will optimize the nanokicked protocol developed by the University of Glasgow to scale up and establish a Manufacturing Guide of allogeneic nanokicked human mesenchymal stromal cells derived from adipose tissue in compliance with GMP manufacture

In collaboration with University of Glasgow, Histocell is scaling up and optimizing the manufacturing protocol in order to transfer the technology of the nanokicking process in “GMP like” conditions before its final translation to GMP conditions.

Dr Eva Gonzalez, of Histocell said “For Histocell, this project is a good opportunity to include new innovative cell therapy technologies in bone regeneration.”